drugset / Trial / NCT02453191

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

NCT02453191

Phase 1/2 Completed 30 enrolled University of Iowa Amgen · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 30 people will take part in this study conducted by investigators at the University of Iowa.

Timeline

Start
2015-07-13
Primary completion
2019-01-22
Completion
2023-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Talimogene Laherparepvec Other / unclassified 4 ml Other

Indications